What does the NextGen Targeted & Immunotherapy Panel at Metropolis Healthcare include?
It evaluates somatic mutations, gene fusions, CNVs, TMB, MSI, and PD-L1 expression to guide precision therapy.
How does Metropolis Healthcare perform this comprehensive panel?
Metropolis Healthcare uses high-depth NGS for genomic analysis and validated IHC for PD-L1, ensuring accurate biomarker assessment.
Who should consider taking this test at Metropolis Healthcare?
Patients with solid tumors requiring molecular and immunotherapy guidance for personalized treatment planning should consider this panel.
Is fasting required for this test at Metropolis Healthcare?
No fasting is needed; tumor tissue and/or blood samples are used as per clinical recommendations.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to extensive sequencing and immunohistochemistry evaluation.
Can this test at Metropolis Healthcare help guide immunotherapy decisions?
Yes, TMB, MSI, and PD-L1 results help clinicians determine suitability for immune checkpoint inhibitors.
How accurate is the Targeted & Immunotherapy Panel at Metropolis Healthcare?
Metropolis Healthcare ensures high precision through validated NGS and IHC protocols under strict quality control.
Does this panel support long-term cancer treatment planning at Metropolis Healthcare?
Yes, it provides comprehensive molecular and immunotherapy insights to guide personalized therapy and monitoring.